专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US6025444A Cinnamic acid derivative 失效
标题翻译：肉桂酸衍生物
公开(公告)号：US6025444A
公开(公告)日：2000-02-15
申请号：US863933
申请日：1997-05-27
申请人： Michinori Waki , Kenji Miyamoto , Yoshihiro Motani
发明人： Michinori Waki , Kenji Miyamoto , Yoshihiro Motani
IPC分类号： C07C217/08 , C07C219/10 , C07C229/22 , C07C233/51 , C07C237/08 , C07C237/12 , C07K5/06 , C07K5/083 , C08B37/00 , C08B37/08 , C08L5/08 , C08F8/32
CPC分类号： C07C217/08 , C07C219/10 , C07C229/22 , C07C233/51 , C07C237/08 , C07C237/12 , C07K5/06026 , C07K5/0806 , C08B37/003 , C08B37/0063 , C08L5/08
摘要： The invention provides a cinnamic acid derivative having a novel spacer introduced into cinnamic acid which is photodimerizable, a cinnamic acid-polysaccharide derivative photocurable with high sensitivity and efficiency obtainable by introducing the above cinnamic acid derivative into a host polysaccharide such as a glycosaminoglycan, and a photocrosslinked cinnamic acid-polysaccharide derivative obtainable by exposing the same cinnamic acid-polysaccharide derivative to ultraviolet light irradiation.
摘要翻译：本发明提供了一种肉桂酸衍生物，其具有引入肉桂酸中的新型间隔基，其可被光可定向化，肉桂酸 - 多糖衍生物可以通过将上述肉桂酸衍生物引入宿主多糖如糖胺聚糖中而获得，其具有高灵敏度和高效率可光固化，通过将相同的肉桂酸 - 多糖衍生物暴露于紫外线照射而获得的光交联肉桂酸 - 多糖衍生物。

2. 发明授权

US5840510A Reagent for endotoxin assay and method for endotoxin assay using the same 失效
标题翻译：用于内毒素测定的试剂和使用其的内毒素测定方法
公开(公告)号：US5840510A
公开(公告)日：1998-11-24
申请号：US885176
申请日：1997-06-30
申请人： Shigenori Tanaka , Hiroshi Tamura , Kazuhiro Aita
发明人： Shigenori Tanaka , Hiroshi Tamura , Kazuhiro Aita
IPC分类号： G01N33/543 , G01N33/579 , C12Q1/37 , C12Q1/00 , C12Q1/34 , C12Q1/56
CPC分类号： G01N33/579 , G01N2333/811 , Y10S435/967
摘要： This invention provides (1) a reagent for endotoxin assay which comprises aprotinin and a limulus amebocyte lysate reagent, (2) a kit for endotoxin assay which comprises the limulus amebocyte lysate reagent and a reagent containing aprotinin, (3) a method for assaying endotoxin in a sample using the limulus amebocyte lysate reagent in which aprotinin is added to the lysate reagent and/or the sample, (4) a method for assaying endotoxin in a serine protease-containing sample using the limulus amebocyte lysate reagent in which the sample is allowed to contact with an aprotinin-immobilized insoluble carrier in advance of endotoxin assay, (5) a carrier for pretreating a serine protease-containing sample on which aprotinin is immobilized, (6) a method for inhibiting factor G activation in which aprotinin is added to the limulus amebocyte lysate reagent and (7) a factor G activation inhibitor which comprises aprotinin as an active ingredient. Endotoxin assay can be effected based on the factor C system reaction, without influences of factor G contained in the limulus amebocyte lysate reagent and/or serine proteases contained in samples.
摘要翻译：本发明提供（1）含有抑肽酶和鲎变形细胞裂解物试剂的内毒素试剂，（2）包含鲎变形细胞裂解物试剂和含有抑肽酶的试剂的内毒素试剂盒，（3）检测内毒素的方法在使用鲎变形细胞裂解物试剂的样品中，其中将抑肽酶加入到裂解物试剂和/或样品中，（4）使用鲎变形细胞裂解物试剂测定含丝氨酸蛋白酶样品中的内毒素的方法，其中样品是在内毒素测定之前允许与抑肽酶固定的不溶性载体接触，（5）用于预处理含有抑肽酶的丝氨酸蛋白酶的样品的载体，（6）抑制因子G激活的方法，其中加入抑肽酶到鲎变形细胞裂解物试剂和（7）包含抑肽酶作为活性成分的因子G激活抑制剂。内毒素测定可以基于因子C系统反应进行，而不受样品中包含的鲎变形细胞裂解物试剂和/或丝氨酸蛋白酶中所含因子G的影响。

3. 发明授权

US5496718A Chondroitinase ABC isolated from proteus vulgaris ATCC 6896 失效
标题翻译：从普通寻常型ATCC 6896中分离的软骨素酶ABC
公开(公告)号：US5496718A
公开(公告)日：1996-03-05
申请号：US082853
申请日：1993-06-23
申请人： Nobukazu Hashimoto , Hideo Mochizuki , Akio Hamai
发明人： Nobukazu Hashimoto , Hideo Mochizuki , Akio Hamai
IPC分类号： A61K38/43 , A61K38/00 , C12N9/16 , C12N9/20 , C12N9/88 , C01G17/04 , C12N1/12
CPC分类号： C12N9/88 , A61K38/00 , G03C2001/0471 , Y10S435/873
摘要： A crystallizable, purified chondroitinase ABC having a molecular weight of about 100,000 dalton by the measurement of the SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and the measurement by the gel permeation chromatography method, having alanine as the N-terminal amino acid and proline as the C-terminal amino acid. A process for the purification of the crystallizable purified chondroitinase ABC comprising removing nucleic acid from an surfactant solution extract obtained from cells of chondroitinase ABC-producing microorganisms and chromatographically treating by concentration gradient elution using a weak cation exchange resin or a strong cation exchange resin. A composition comprising a chondroitinase and serum albumin, gelatin, or a nonionic surfactant. The chondroitinase ABC is isolated from Proteus vulgaris ATCC 6896.
摘要翻译：通过SDS-聚丙烯酰胺凝胶电泳（SDS-PAGE）的测量和通过凝胶渗透色谱法测定的具有约100,000道尔顿分子量的可结晶纯化的软骨素酶ABC，其具有丙氨酸作为N-末端氨基酸和脯氨酸作为C末端氨基酸。一种用于纯化可结晶的纯化软骨素酶ABC的方法，包括从获自软骨素酶ABC微生物的细胞获得的表面活性剂溶液提取物中除去核酸，并使用弱阳离子交换树脂或强阳离子交换树脂进行色谱法处理。包含软骨素酶和血清白蛋白，明胶或非离子表面活性剂的组合物。软骨素酶ABC从普通变形杆菌ATCC 6896中分离。

4. 发明授权

US6001630A Pharmaceutical compositions of chondroitinase ABC isolated from Proteus vulgaris ATCC 6896 失效
标题翻译：从普通变形杆菌ATCC 6896分离的软骨素酶ABC的药物组合物
公开(公告)号：US6001630A
公开(公告)日：1999-12-14
申请号：US444309
申请日：1995-05-18
申请人： Shinichi Ichikawa , Misako Torikai , Isao Miyachi
发明人： Shinichi Ichikawa , Misako Torikai , Isao Miyachi
IPC分类号： A61K38/00 , C12N9/88 , A61K38/51 , A61K38/52 , C12N9/26
CPC分类号： C12N9/88 , A61K38/00 , G03C2001/0471
摘要： A crystallizable, purified chondroitinase ABC having a molecular weight of about 100,000 dalton by the measurement of the SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and the measurement by the gel permeation chromatography method, having alanine as the N-terminal amino acid and proline as the C-terminal amino acid is disclosed. A process for the purification of the crystallizable purified chondroitinase ABC comprising removing nucleic acid from an surfactant solution extract obtained from cells of chondroitinase ABC-producing microorganisms and chromatographically treating by concentration gradient elution using a weak cation exchange resin or a strong cation exchange resin is disclosed. A composition comprising a chondroitinase and serum albumin, gelatin, or a nonionic surfactant is used to treat disc displacement. The enzyme is isolate from Proteus vulgaris ATCC 6896.
摘要翻译：通过SDS-聚丙烯酰胺凝胶电泳（SDS-PAGE）的测量和通过凝胶渗透色谱法测定的具有约100,000道尔顿分子量的可结晶纯化的软骨素酶ABC，其具有丙氨酸作为N-末端氨基酸和脯氨酸因为公开了C-末端氨基酸。公开了一种纯化可结晶纯化软骨素酶ABC的方法，包括从由软骨素酶ABC产生的微生物的细胞获得的表面活性剂溶液提取物中除去核酸，并使用弱阳离子交换树脂或强阳离子交换树脂进行色谱法处理。。使用包含软骨素酶和血清白蛋白，明胶或非离子表面活性剂的组合物来治疗椎间盘移位。该酶是从普通变形菌ATCC 6896中分离的。

5. 发明授权

US5763504A Photcurable glycosaminoglycan derivatives, crosslinked glycosaminoglycans and method of production thereof 失效
标题翻译：光电性糖胺聚糖衍生物，交联糖胺聚糖及其生产方法
公开(公告)号：US5763504A
公开(公告)日：1998-06-09
申请号：US476236
申请日：1995-06-07
申请人： Takehisa Matsuda , Minoo J. Moghaddam , Katsukiyo Sakurai
发明人： Takehisa Matsuda , Minoo J. Moghaddam , Katsukiyo Sakurai
IPC分类号： A61K47/36 , A61K31/715 , A61K31/726 , A61K31/727 , A61K31/737 , A61K47/48 , A61L27/00 , A61L27/20 , A61L31/04 , A61L33/00 , A61L33/08 , A61L33/10 , A61P43/00 , C08B37/00 , C08B37/08 , C08B37/10 , C08F251/00 , C08L5/00 , C08L5/08 , C08L5/10 , C08L51/02 , C08G64/00 , A61K9/50 , C08G69/08 , C08G73/10
CPC分类号： B82Y5/00 , A61K47/48961 , A61L27/20 , A61L31/042 , A61L33/08 , C08B37/0063
摘要： Photocurable glycosaminoglycan (GAG) derivatives and crosslinked glycosaminoglycans, which are highly safe and biocompatible, a method of preparing such photocurable GAG derivatives readily moldable by casting using a solvent when desired, by which method unreacted substances causative of adverse effects can be readily eliminated, and a method of producing the crosslinked GAGs and medical materials based on the photocurable GAG derivatives or crosslinked GAGs are provided. The photocurable GAG derivatives comprise a glycosaminoglycan and a photoreactive compound bound thereto and can be produced, for example, by subjecting hydroxyl or carboxyl groups of the glycosaminoglycan to esterification reaction or amidation reaction, respectively, with the photoreactive compound. The crosslinked GAGs are derived from the photocurable GAG derivatives by intermolecular crosslinking of the photoreactive compound bound thereto.
摘要翻译：可光固化的糖胺聚糖（GAG）衍生物和交联的糖胺聚糖，其是高度安全和生物相容的，制备这种可光固化的GAG衍生物的方法，其易于通过在需要时使用溶剂浇铸而成型，由此可以容易地消除引起不利影响的未反应物质，以及提供了基于可光固化的GAG衍生物或交联的GAG生产交联的GAG和医疗材料的方法。可光固化的GAG衍生物包含糖胺聚糖和结合到其上的光反应性化合物，并且可以例如通过使糖胺聚糖的羟基或羧基与光反应性化合物分别进行酯化反应或酰胺化反应来制备。交联的GAG通过与其结合的光反应性化合物的分子间交联衍生自可光固化的GAG衍生物。

6. 发明授权

US5688250A Syringe 失效
标题翻译：注射器
公开(公告)号：US5688250A
公开(公告)日：1997-11-18
申请号：US482856
申请日：1995-06-07
申请人： Masateru Naganuma
发明人： Masateru Naganuma
IPC分类号： A61M5/24 , A61M5/315 , A61M5/28
CPC分类号： A61M5/2466 , A61M5/24 , A61M5/315 , A61M2005/2407 , A61M2005/247 , A61M2005/31508 , A61M5/31586
摘要： A cartridge-type syringe in which a cartridge, having liquid medicine or the like sealed therein, is inserted in a holder having a discharge needle at its distal end, and the cartridge is advanced to cause the discharge needle to pierce it, thereby injecting the liquid medicine or the like into an object, and when a piston rod of the cartridge is pushed to cause the discharge needle to pierce, the liquid medicine or the like will not be discharged in error in a large amount. In particular, there is provided a releaseable lock mechanism by which when a piston rod 15 is pushed, the piston rod 15 advances together with a tubular body 11 of a cartridge 10 without moving a piston 14 within the tubular body 11. For example, in a first embodiment, when a discharge needle 5 pierces the distal end of the tubular body 11, an engagement member 24 is pressed to be brought into intimate contact with the piston rod 15, thereby releasing the lock mechanism 21, and by pushing the piston rod 15, the piston 14 is driven to advance within the tubular body 11, thereby discharging liquid medicine or the like via the discharge needle 5.
摘要翻译：将其中密封有液体药物等的药筒插入到其远端具有放电针的保持器中的药筒型注射器，并且推进药筒以使排出针刺穿它，从而将液体药剂等成为物体，并且当推动药筒的活塞杆使排气针刺穿时，液体药剂等不会大量错误地排出。特别地，提供了一种可释放的锁定机构，当推动活塞杆15时，活塞杆15与筒体10的管状体11一起前进，而不会在管状体11内移动活塞14.例如，在在第一实施方式中，当排出针5刺穿管状体11的前端时，卡合构件24被按压以与活塞杆15紧密接触，从而释放锁定机构21，并且通过推动活塞杆如图15所示，活塞14被驱动在管状体11内前进，从而经由排出针5排出药液等。

7. 发明授权

US5801162A Dermatan sulfate compositions and antithrombotic compositions containing same 失效
标题翻译：硫酸皮肤素组合物和含有它们的抗血栓形成组合物
公开(公告)号：US5801162A
公开(公告)日：1998-09-01
申请号：US446662
申请日：1995-08-28
申请人： Akikazu Takada , Junichi Onaya , Mikio Arai , Satoshi Miyauchi , Mamoru Kyogashima , Keiichi Yoshida
发明人： Akikazu Takada , Junichi Onaya , Mikio Arai , Satoshi Miyauchi , Mamoru Kyogashima , Keiichi Yoshida
IPC分类号： A61K31/715 , A61K31/726 , A61K31/737 , A61K38/36 , A61K38/49 , A61P7/02 , A61P9/10 , C08B37/00 , C08B37/08 , C08L5/00 , C08L5/08
CPC分类号： A61K38/49 , A61K31/715 , A61K31/726 , A61K31/737 , C08B37/0069 , C08L5/00 , C08L5/08
摘要： Dermatan sulfate compositions having certain characteristics have been found to have thrombolytic activity. Dermatan sulfate combined with tissue plasminogen activator (t-PA) enhances the thrombolytic activity of t-PA. Antithrombotic compositions containing dermatan sulfates can be used for treating various thrombotic diseases.
摘要翻译： PCT No.PCT / JP94 / 01643 Sec。 371日期：1995年8月28日 102（e）日期1995年8月28日PCT 1994年9月30日PCT公布。公开号WO95 / 09188 日期1995年4月6日已经发现具有某些特征的硫酸皮肤素组合物具有溶栓活性。硫酸皮肤素组合纤维蛋白溶酶原激活剂（t-PA）增强了t-PA的溶栓活性。含有硫酸皮肤素的抗血栓组合物可用于治疗各种血栓性疾病。

8. 发明授权

US5648230A Endotoxin stabilizing agent, endotoxin composition and method for assaying endotoxin 失效
标题翻译：内毒素稳定剂，内毒素组成和测定内毒素的方法
公开(公告)号：US5648230A
公开(公告)日：1997-07-15
申请号：US474722
申请日：1995-06-07
申请人： Hiroshi Tamura , Shigenori Tanaka , Jun Aketagawa , Toshio Oda
发明人： Hiroshi Tamura , Shigenori Tanaka , Jun Aketagawa , Toshio Oda
IPC分类号： G01N33/579 , C12Q1/34
CPC分类号： G01N33/579
摘要： An endotoxin stabilizing agent is provided, which is useful in order to maintain the endotoxin activity of a specimen or a reference standard in a stable state for a prolonged period of time and to prepare an endotoxin reference standard having a reduced intervial variation, being stable for a long time in the form of, in particular, a solution and withstanding repeated use. An endotoxin composition comprising the above-mentioned endotoxin stabilizing agent and endotoxin and a method for assaying endotoxin by using the same are also provided. The endotoxin stabilizing agent comprises: (1) at least one substance selected from the group consisting of aminoalcohols, polyhydric alcohols, nonionic surfactants, polysucroses and chelating agents; (2) at least aminoalcohol and polyhydric alcohol; (3) with the polyhydric alcohol being preferably glycerol or its derivative; (4) polyethylene glycol as an effective ingredient in addition to the components (1) to (3); or (5) at least polysucrose, and an alkaline earth metal salt and/or polyethylene glycol as an effective ingredient. The endotoxin composition comprises the above-identified endotoxin stabilizing agent. The method for assaying endotoxin comprises adding the above-described endotoxin stabilizing agent to a specimen to thereby stabilize the activity of endotoxin in the specimen.
摘要翻译：提供了一种内毒素稳定剂，其可用于将试样或参考标准品的内毒素活性长时间维持在稳定状态，并制备具有减小的间隙变化的内毒素参照标准物，其对于很长一段时间的形式，特别是一个解决方案，并承受反复使用。还提供了包含上述内毒素稳定剂和内毒素的内毒素组合物和使用该内毒素测定内毒素的方法。所述内毒素稳定剂包括：（1）选自氨基醇，多元醇，非离子表面活性剂，多糖和螯合剂中的至少一种物质; （2）至少氨基醇和多元醇; （3）多元醇优选为甘油或其衍生物; （4）除了组分（1）至（3）之外的聚乙二醇作为有效成分; 或（5）至少聚蔗糖，以及碱土金属盐和/或聚乙二醇作为有效成分。内毒素组合物包含上述内毒素稳定剂。用于测定内毒素的方法包括向样品中加入上述内毒素稳定剂，从而稳定样品中内毒素的活性。

9. 发明授权

US5624839A Process for culturing hepatocytes for formation of spheroids 失效
标题翻译：培养肝细胞以形成球状体的方法
公开(公告)号：US5624839A
公开(公告)日：1997-04-29
申请号：US453932
申请日：1995-05-30
申请人： Toshikazu Yada , Norio Koide , Koji Kimata
发明人： Toshikazu Yada , Norio Koide , Koji Kimata
IPC分类号： A61K35/407 , C08B37/00 , C08B37/08 , C12N5/00 , C12N5/071 , A61K31/715 , C07H1/00
CPC分类号： C12N5/0068 , C08B37/0063 , C12N5/0671 , C12N2501/90 , C12N2501/905 , C12N2501/91 , C12N2533/70
摘要： Hepatocytes spheroids can be formed by culturing hepatocytes in a culture vessel using a lipid-bound glycosaminoglycan as a culture substrate. Floating spheroids of hepatocytes can be obtained efficiently, which are capable of maintaining liver-specific functions and of keeping the spheroid form stably for a prolonged period of time.
摘要翻译：可以通过使用脂质结合的糖胺聚糖作为培养基质在培养容器中培养肝细胞来形成肝细胞球形体。可以有效地获得肝细胞的浮球，其能够保持肝脏特异性的功能并且保持球状体长时间稳定地形成。

10. 发明授权

US5401647A Method of preparing Limulus amoebocyte lysate 失效
标题翻译：制备鲎变形细胞裂解物的方法
公开(公告)号：US5401647A
公开(公告)日：1995-03-28
申请号：US859411
申请日：1992-05-27
申请人： Shigenori Tanaka , Jun Aketagawa , Yuko Shibata
发明人： Shigenori Tanaka , Jun Aketagawa , Yuko Shibata
IPC分类号： G01N33/579 , C12N11/06 , C12N11/08 , C12N11/14 , C12Q1/37
CPC分类号： G01N33/579 , Y10T436/25125
摘要： Disclosed is a method of preparing limulus amoebocyte lysate substantially free from factor G which comprises bringing limulus amoebocyte lysate into contact with an insoluble carrier on which a (1.fwdarw.3)-.beta.-D-glucoside structural portion represented by the following formula [I] produced by depolymerizing and/or fractionating a carbohydrate chain is immobilized: ##STR1## wherein n represents an integer of 2 to 370.
摘要翻译： PCT No.PCT / JP91 / 01308 371日期：1992年5月27日 102（e）日期1992年5月27日PCT 1991年9月27日PCT PCT。公开号WO92 / 06381 日期：1992年4月16日。公开是一种制备基本上不含因子G的鲎变形细胞裂解物的方法，其包括使鲎变形细胞裂解物与其上含有（1-> 3）-β-D-葡萄糖苷结构部分的不溶性载体接触由通过解聚和/或分馏碳水化合物链产生的下式[I]表示的化合物：其中n表示2至370的整数。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式